Skip to main content
. 2013 Jun 17;110(27):E2510–E2517. doi: 10.1073/pnas.1309171110

Fig. 3.

Fig. 3.

In vivo efficacy of TCA1 in mouse models. In an acute Mtb infection mouse model (2 wk infection) followed by 4 wk of drug treatment, TCA1 showed significant bactericidal activity in (A) lungs and (B) spleen both alone (100 mg/kg) and combined with (40 mg/kg) INH (25 mg/kg) or RIF (10 mg/kg). The low activity of RIF as a monotherapy in this model is consistent with what has been observed in a previous study (14). In a chronic TB infection mouse model (4 wk low-dose infection) followed by 4 wk of drug treatment, TCA1 showed activity in (C) lungs and (D) spleen both alone (100 mg/kg) and combined with (40 mg/kg) INH (25 mg/kg) or RIF (10 mg/kg; P value < 0.05). Mice were gavaged with TCA1 1 time/d for 5 d/wk. RIF and INH were administered in drinking water.